Recent Advancements in the Development of Anti-Breast Cancer Synthetic Small Molecules

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2021 Dec 24

PMID 34946704

Citations 5

Authors

Eslam B Elkaeed

Hayam A Abd El Salam

Ahmed Sabt

Ghada H Al-Ansary

Wagdy M Eldehna

Affiliations

Soon will be listed here.

Abstract

Among all cancer types, breast cancer (BC) still stands as one of the most serious diseases responsible for a large number of cancer-associated deaths among women worldwide, and diagnosed cases are increasing year by year worldwide. For a very long time, hormonal therapy, surgery, chemotherapy, and radiotherapy were used for breast cancer treatment. However, these treatment approaches are becoming progressively futile because of multidrug resistance and serious side effects. Consequently, there is a pressing demand to develop more efficient and safer agents that can fight breast cancer belligerence and inhibit cancer cell proliferation, invasion and metastasis. Currently, there is an avalanche of newly designed and synthesized molecular entities targeting multiple types of breast cancer. This review highlights several important synthesized compounds with promising anti-BC activity that are categorized according to their chemical structures.

Citing Articles

In vitro and in silico studies of a Zn(II) complex as a potential therapeutic agent for breast cancer.

Anjomshoa M, Amirheidari B, Janczak J, Sahihi M, Abolhassani Y, Farsinejad A Sci Rep. 2024; 14(1):29138.

PMID: 39587128 PMC: 11589879. DOI: 10.1038/s41598-024-79644-0.

Synthesis and effect of 4-acetylphenylamine-based imidazole derivatives on migration and growth of 3D cultures of breast, prostate and brain cancer cells.

Golciene B, Vaickelioniene R, Endriulaityte U, Mickevicius V, Petrikaite V Sci Rep. 2024; 14(1):28065.

PMID: 39543257 PMC: 11564686. DOI: 10.1038/s41598-024-76533-4.

Design and synthesis of phosphoryl-substituted steroidal pyridazines (Pho-STPYRs) as potent estrogen receptor alpha inhibitors: targeted treatment of hormone-dependent breast cancer cells.

Volkova Y, Scherbakov A, Dzichenka Y, Komkov A, Bogdanov F, Salnikova D RSC Med Chem. 2024; 15(7):2380-2399.

PMID: 39026643 PMC: 11253874. DOI: 10.1039/d4md00153b.

Tuning of the Anti-Breast Cancer Activity of Betulinic Acid via Its Conversion to Ionic Liquids.

Ossowicz-Rupniewska P, Klebeko J, Georgieva I, Apostolova S, Struk L, Todinova S Pharmaceutics. 2024; 16(4).

PMID: 38675157 PMC: 11053683. DOI: 10.3390/pharmaceutics16040496.

2-{5-[(,2)-2-Chloro-3-(4-nitrophenyl)-2-propenylidene]-4-oxo-2-thioxothiazolidin-3-yl}-3-methylbutanoic Acid as a Potential Anti-Breast Cancer Molecule.

Buzun K, Gornowicz A, Lesyk R, Kryshchyshyn-Dylevych A, Gzella A, Czarnomysy R Int J Mol Sci. 2022; 23(8).

PMID: 35456915 PMC: 9032233. DOI: 10.3390/ijms23084091.

References

Gamal El-Din M, El-Gamal M, Abdel-Maksoud M, Yoo K, Oh C . Synthesis and in vitro antiproliferative activity of new 1,3,4-oxadiazole derivatives possessing sulfonamide moiety. Eur J Med Chem. 2014; 90:45-52. DOI: 10.1016/j.ejmech.2014.11.011. View

El-Faham A, Farooq M, Almarhoon Z, Abd Alhameed R, Wadaan M, de la Torre B . Di- and tri-substituted s-triazine derivatives: Synthesis, characterization, anticancer activity in human breast-cancer cell lines, and developmental toxicity in zebrafish embryos. Bioorg Chem. 2019; 94:103397. DOI: 10.1016/j.bioorg.2019.103397. View

Mohan C, Srinivasa V, Rangappa S, Mervin L, Mohan S, Paricharak S . Trisubstituted-Imidazoles Induce Apoptosis in Human Breast Cancer Cells by Targeting the Oncogenic PI3K/Akt/mTOR Signaling Pathway. PLoS One. 2016; 11(4):e0153155. PMC: 4838272. DOI: 10.1371/journal.pone.0153155. View

Arshad M, Bhat A, Pokharel S, Kim J, Lee E, Athar F . Synthesis, characterization and anticancer screening of some novel piperonyl-tetrazole derivatives. Eur J Med Chem. 2013; 71:229-36. DOI: 10.1016/j.ejmech.2013.11.008. View

Ahmed E, Abdel Latif N, El-Mansy M, Elserwy W, Abdelhafez O . VEGFR-2 inhibiting effect and molecular modeling of newly synthesized coumarin derivatives as anti-breast cancer agents. Bioorg Med Chem. 2020; 28(5):115328. DOI: 10.1016/j.bmc.2020.115328. View

Maughan K, Lutterbie M, Ham P . Treatment of breast cancer. Am Fam Physician. 2010; 81(11):1339-46. View

Andre F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo H . Alpelisib for -Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2019; 380(20):1929-1940. DOI: 10.1056/NEJMoa1813904. View

Wang S, Zhang Y, Ren T, Wu Q, Lu H, Qin X . A novel 4-aminoquinazoline derivative, DHW-208, suppresses the growth of human breast cancer cells by targeting the PI3K/AKT/mTOR pathway. Cell Death Dis. 2020; 11(6):491. PMC: 7327080. DOI: 10.1038/s41419-020-2690-y. View

Sengmany S, Sitter M, Leonel E, Le Gall E, Loirand G, Martens T . Synthesis and biological evaluation of 3-amino-, 3-alkoxy- and 3-aryloxy-6-(hetero)arylpyridazines as potent antitumor agents. Bioorg Med Chem Lett. 2019; 29(5):755-760. DOI: 10.1016/j.bmcl.2018.12.050. View

10.

Fragomeni S, Sciallis A, Jeruss J . Molecular Subtypes and Local-Regional Control of Breast Cancer. Surg Oncol Clin N Am. 2017; 27(1):95-120. PMC: 5715810. DOI: 10.1016/j.soc.2017.08.005. View

11.

Dawood D, Nossier E, Ali M, Mahmoud A . Synthesis and molecular docking study of new pyrazole derivatives as potent anti-breast cancer agents targeting VEGFR-2 kinase. Bioorg Chem. 2020; 101:103916. DOI: 10.1016/j.bioorg.2020.103916. View

12.

Ma C, Wang Y, Dong F, Wang Z, Zhao Y, Shan Y . Synthesis and antitumor activity of isolongifoleno[7,8-d]thiazolo[3,2-a]pyrimidine derivatives via enhancing ROS level. Chem Biol Drug Des. 2019; 94(2):1457-1466. DOI: 10.1111/cbdd.13522. View

13.

Lakshmithendral K, Saravanan K, Elancheran R, Archana K, Manikandan N, Arjun H . Design, synthesis and biological evaluation of 2-(phenoxymethyl)-5-phenyl-1,3,4-oxadiazole derivatives as anti-breast cancer agents. Eur J Med Chem. 2019; 168:1-10. DOI: 10.1016/j.ejmech.2019.02.033. View

14.

OBoyle N, Ana G, Kelly P, Nathwani S, Noorani S, Fayne D . Synthesis and evaluation of antiproliferative microtubule-destabilising combretastatin A-4 piperazine conjugates. Org Biomol Chem. 2019; 17(25):6184-6200. DOI: 10.1039/c9ob00558g. View

15.

Zhang Y, Wang Y, Zhao Y, Gu W, Zhu Y, Wang S . Novel camphor-based pyrimidine derivatives induced cancer cell death through a ROS-mediated mitochondrial apoptosis pathway. RSC Adv. 2022; 9(51):29711-29720. PMC: 9071996. DOI: 10.1039/c9ra05900h. View

16.

Guo H, Diao Q . The Anti-Breast Cancer Potential of Bis-Isatin Scaffolds. Curr Top Med Chem. 2020; 20(16):1499-1503. DOI: 10.2174/1568026620666200310124416. View

17.

Zureick A, McFadden K, Mody R, Koschmann C . Successful treatment of a -mutant glioblastoma with everolimus. BMJ Case Rep. 2019; 12(5). PMC: 6557420. DOI: 10.1136/bcr-2018-227734. View

18.

Reddy S, Mendonza J, Makani V, Bhadra M, Uppuluri V . Synthesis of some novel methyl β-orsellinate based 3, 5-disubstituted isoxazoles and their anti-proliferative activity: Identification of potent leads active against MCF-7 breast cancer cell. Bioorg Chem. 2020; 105:104374. DOI: 10.1016/j.bioorg.2020.104374. View

19.

Exman P, Barroso-Sousa R, Tolaney S . Evidence to date: talazoparib in the treatment of breast cancer. Onco Targets Ther. 2019; 12:5177-5187. PMC: 6612288. DOI: 10.2147/OTT.S184971. View

20.

Sardesai S, Storniolo A . Lapatinib: an oral dual tyrosine kinase inhibitor for HER-2-positive breast cancer. Womens Health (Lond). 2015; 11(3):281-94. DOI: 10.2217/whe.15.9. View